US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
|
Scooped by
Gilbert C FAURE
onto Allergy (and clinical immunology) July 24, 2015 5:35 AM
|